Additionally, antibodies targeting the Interleukin-6 receptor (anti-IL6R), such as tocilizumab, successfully counteracted CRS symptoms in CAR-T cell-treated patients with B-ALL [55, 96]. The gene discussed is IL6R; the disease is congenital rubella syndrome.